Systematic Identification of Human Melanoma Antigens Using Serial Analysis of Gene Expression (SAGE)

To identify new melanoma antigens using systematic gene expression analysis combined with rapid screening of patient sera for immunogenicity, a serial analysis of gene expression (SAGE) method was applied to profile transcripts in a highly pigmented melanoma cell line SKmel23. 25,997 SAGE tags consisting of 10,382 unique transcripts were sequenced. This melanoma SAGE library was compared with a testis SAGE library and the colon SAGE database, and to the cDNA database obtained by random sequencing of a melanocyte cDNA library. Among the 15 tags finally selected with criteria of preferential expression on melanoma and melanocytes at relatively high frequency, two tags were further analyzed for their structure and immunogenicity. One was identified as PAX3, and its isoform, PAX3d, was found to be dominantly expressed in melanoma and melanocytes. The other was derived from a novel gene and its full-length cDNA clone was isolated. Preferential expression of these genes in melanoma and melanocytes was confirmed by RT-PCR and Northern blot analysis. The recombinant bacterial PAX3d protein was recognized by serum IgG from some patients with melanoma and Vogt-Koyanagi-Harada (VKH) disease but not from healthy individuals, indicating that PAX3d is a new melanocyte-specific antigen immunogenic in patients with melanoma or VKH disease. The authors report two melanocyte/melanoma-specific molecules, which may be useful for development of diagnosis or treatment of these pigment disorders. In addition, a system using SAGE and immunoscreening with patients' sera is shown to be an efficient method for the systematic identification of tumor antigens.

[1]  K. Taira,et al.  Inhibition of growth and invasive ability of melanoma by inactivation of mutated BRAF with lentivirus-mediated RNA interference , 2004, Oncogene.

[2]  C. Huber,et al.  Partial tyrosinase‐specific self tolerance by HLA‐A*0201‐restricted cytotoxic T lymphocytes in mice and man , 2004, International journal of cancer.

[3]  C. Pritchard,et al.  Alternative splicing of Pax3 produces a transcriptionally inactive protein. , 2003, Gene.

[4]  M. Raffeld,et al.  Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes , 2002, Science.

[5]  Kenneth H Buetow,et al.  An anatomy of normal and malignant gene expression , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[6]  Gerd Ritter,et al.  Identification of cancer/testis genes by database mining and mRNA expression analysis , 2002, International journal of cancer.

[7]  Ji Huang,et al.  [Serial analysis of gene expression]. , 2002, Yi chuan = Hereditas.

[8]  Y. Suzuki,et al.  Tumor antigens isolated from a patient with vitiligo and T-cell-infiltrated melanoma. , 2001, Cancer research.

[9]  J. Eberle,et al.  The Bax/Bcl-2 ratio determines the susceptibility of human melanoma cells to CD95/Fas-mediated apoptosis. , 2001, The Journal of investigative dermatology.

[10]  S. Rosenberg,et al.  Isolation of a New Melanoma Antigen, MART-2, Containing a Mutated Epitope Recognized by Autologous Tumor-Infiltrating T Lymphocytes1 , 2001, The Journal of Immunology.

[11]  F. Marincola,et al.  Phase 1 Study in Patients With Metastatic Melanoma of Immunization With Dendritic Cells Presenting Epitopes Derived From the Melanoma-Associated Antigens MART-1 and gp100 , 2000, Journal of immunotherapy.

[12]  J. Massagué,et al.  Structural basis of Smad2 recognition by the Smad anchor for receptor activation. , 2000, Science.

[13]  G. Landes,et al.  Analysis of human transcriptomes , 1999, Nature Genetics.

[14]  T. Barber,et al.  PAX3 gene structure, alternative splicing and evolution. , 1999, Gene.

[15]  K. Matsushima,et al.  Serial analysis of gene expression in human monocyte-derived dendritic cells. , 1999, Blood.

[16]  K. Matsushima,et al.  Serial analysis of gene expression in human monocytes and macrophages. , 1999, Blood.

[17]  I. Pastan,et al.  Novel genes in the PAGE and GAGE family of tumor antigens found by homology walking in the dbEST database. , 1999, Cancer research.

[18]  Y. Kawakami.  Immunotherapy Using T Cell Defined Tumor Antigens for Melanoma , 1998, Microbiology and immunology.

[19]  A Sette,et al.  Identification of a shared HLA-A*0201-restricted T-cell epitope from the melanoma antigen tyrosinase-related protein 2 (TRP2). , 1998, Cancer research.

[20]  S. Rosenberg,et al.  A breast and melanoma-shared tumor antigen: T cell responses to antigenic peptides translated from different open reading frames. , 1998, Journal of immunology.

[21]  Lloyd J. Old,et al.  New Paths in Human Cancer Serology , 1998, The Journal of experimental medicine.

[22]  F. Marincola,et al.  Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma , 1998, Nature Medicine.

[23]  Dirk Schadendorf,et al.  Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cells , 1998, Nature Medicine.

[24]  K. Arden,et al.  Identification of a new MAGE gene with tumor-specific expression by representational difference analysis. , 1998, Cancer research.

[25]  I. Pastan,et al.  Discovery of three genes specifically expressed in human prostate by expressed sequence tag database analysis. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[26]  F. Brasseur,et al.  Identification of human testis-specific transcripts and analysis of their expression in tumor cells. , 1997, Biochemical and biophysical research communications.

[27]  M. Pfreundschuh,et al.  Serological analysis of human tumor antigens: molecular definition and implications. , 1997, Molecular medicine today.

[28]  Paul Polakis,et al.  Stabilization of β-Catenin by Genetic Defects in Melanoma Cell Lines , 1997, Science.

[29]  Wei Zhou,et al.  Characterization of the Yeast Transcriptome , 1997, Cell.

[30]  P. Robbins,et al.  Human tumor antigens recognized by T cells. , 1996, Current opinion in immunology.

[31]  F. Oesch,et al.  Inverse relationship of melanocyte differentiation antigen expression in melanoma tissues and CD8+ cytotoxic‐T‐cell responses: Evidence for immunoselection of antigen‐loss variants in vivo , 1996, International journal of cancer.

[32]  S. Rosenberg,et al.  Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[33]  H. Grey,et al.  Induction of anti-tumor cytotoxic T lymphocytes in normal humans using primary cultures and synthetic peptide epitopes. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[34]  T. Friedman,et al.  A frameshift mutation in the HuP2 paired domain of the probable human homolog of murine Pax-3 is responsible for Waardenburg syndrome type 1 in an Indonesian family. , 1992, Human molecular genetics.

[35]  L. Old,et al.  Cell surface antigens of human malignant melanoma: mixed hemadsorption assays for humoral immunity to cultured autologous melanoma cells. , 1976, Proceedings of the National Academy of Sciences of the United States of America.

[36]  並木 剛.  Genomic alterations in primary cutaneous melanomas detected by metaphase comparative genomic hybridization with laser capture or manual microdissection : 6p gains may predict poor outcome , 2005 .

[37]  C. Garbe,et al.  Detection of micrometastasis in sentinel lymph nodes of patients with primary cutaneous melanoma. , 2001, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[38]  S. Rosenberg,et al.  Recognition of shared melanoma antigens in association with major HLA-A alleles by tumor infiltrating T lymphocytes from 123 patients with melanoma. , 2000, Journal of immunotherapy.

[39]  R H Hruban,et al.  Gene expression profiles in normal and cancer cells. , 1997, Science.

[40]  P. Robbins,et al.  Stabilization of beta-catenin by genetic defects in melanoma cell lines. , 1997, Science.

[41]  M. Tassabehji,et al.  Mutations in the PAX3 gene causing Waardenburg syndrome type 1 and type 2 , 1993, Nature Genetics.